Skip to main content

Immune Globulin Intravenous And Subcutaneous Dosage

Medically reviewed by Drugs.com. Last updated on Feb 16, 2023.

Applies to the following strengths: 10%

Usual Adult Dose for Primary Immunodeficiency Syndrome

Intravenously:
300 to 600 mg/kg, IV, every 3 to 4 weeks


Subcutaneously:
1.37 x current IV dose in grams / number of weeks between IV doses; administer weekly

Comments:

Use: Treatment of primary humoral immunodeficiency including, but not limited to, congenital agammaglobulinemia, common variable immunodeficiency, X-linked agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies.

Usual Adult Dose for Idiopathic (Immune) Thrombocytopenic Purpura

1 g/kg, IV, on two consecutive days (high dose regimen)
or
0.4 g/kg, IV, on five consecutive days
(total dose 2 g/kg)


Comments:

Use: Treatment of patients with idiopathic thrombocytopenic purpura to raise platelet counts to prevent bleeding or allow surgery to be performed.

Usual Adult Dose for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Loading dose: 2 g/kg, IV, in divided doses, over 2 to 4 consecutive days
Maintenance dose: 1 g/kg, IV, over 1 day; OR 0.5 g/kg, IV, given on 2 consecutive days


Comments:

Uses: Treatment of chronic inflammatory demyelinating polyneuropathy to improve neuromuscular disability and impairment, and for maintenance therapy to prevent relapse.

Usual Adult Dose for Multifocal Motor Neuropathy

Gammagard (R):

IV administration:
Dose range 0.5 to 2.4 grams/kg/month based on clinical response
Initial infusion rate: 0.5 mL/kg/hr (0.8 mg/kg/min)
Maintenance infusion rate: Infusion rate may be advanced if tolerated to 5.4 mL/kg/hr (9 mg/kg/min)

Subcutaneous administration:
Initial Dose is 1.37 x previous intravenous dose divided by # of weeks between intravenous doses.
Maintenance dose is based on clinical response and target IgG trough level.
Initial infusion rate:
40 kg body weight (BW) and greater:
30 mL/site at 20 mL/hr/site.
Under 40 kg BW:
20 mL/site at 15 mL/hr/site
Maintenance infusion rate:
40 kg BW and greater:
30 mL/site at 20 to 30 mL/hr/site.
Under 40 kg BW:
20 mL/site at 15 to 20 mL/hr/site

Usual Pediatric Dose for Primary Immunodeficiency Syndrome

Intravenously:
300 to 600 mg/kg, IV


Subcutaneously:
1.37 x current IV dose in grams / number of weeks between IV doses; administer weekly

Comments:

Use: Treatment of primary humoral immunodeficiency including, but not limited to, congenital agammaglobulinemia, common variable immunodeficiency, X-linked agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies.

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Dose Adjustments


Measles:

Precautions

US BOXED WARNINGS:
THROMBOSIS, RENAL DYSFUNCTION and ACUTE RENAL FAILURE


CONTRAINDICATIONS:

Safety and efficacy have not been established in patients younger than 2 years.


Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:


Storage requirements:

Reconstitution/preparation techniques:

IV compatibility:

Monitoring:

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.